Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
3. Renal denervation is ‘highly unlikely,’ says Medtronic study insider
Medtronic’s clinical trial flop may signal the end for renal denervation in treating hypertension, according to a co-primary principal investigator involved with Medtronic’s SYMPLICITY HTN-3 trial.
2. China wants concessions in Thermo Fisher’s $13.6B Life Tech deal
Chinese regulators plan to give their blessing to Thermo Fisher’s $13.6 billion acquisition of Life Technologies Corp., as long as Thermo agrees to some price cuts and divestitures.
1. Johnson & Johnson’s ortho-clinical diagnostics goes to Carlyle for $4.15B
Private equity firm Carlyle Group signs a binding offer to acquire Johnson & Johnson’s ortho-clinical testing business for $4.15 billion.
